Physician profile
Camilo Gonima
NPI 1316964745
$203,360.81
in general payments reported to CMS, 2019-2025
34 companies · $34K in 2025
The $34K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $12K · 2021: $32K · 2022: $43K · 2023: $42K · 2024: $30K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $103K · Food and Beverage: $2,444 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $102,583.90 |
| Food and Beverage | $2,443.77 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $164,759.53 | 2021-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $33,405.94 | 2019-2022 | |
| Abbvie INC. | $1,566.66 | 2019-2023 | |
| Daiichi Sankyo INC. | $787.23 | 2019-2025 | Injectafer |
| Mayne Pharma Commercial LLC | $453.14 | 2021-2025 | |
| Astellas Pharma US INC | $340.03 | 2019-2025 | Veozah |
| Exeltis, USA INC. | $261.02 | 2019-2023 | Slynd |
| Biogen, INC. | $204.45 | 2024-2025 | Zurzuvae |
| Agile Therapeutics, INC. | $166.36 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $146.99 | 2021-2024 | Exparel |
| Avion Pharmaceuticals | $141.76 | 2020-2023 | Balcoltra |
| Sumitomo Pharma America, INC. | $129.10 | 2023-2025 | Myfembree, Gemtesa |
| Shield Therapeutics INC | $124.91 | 2022-2024 | Accrufer |
| Myovant Sciences INC. | $117.12 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $95.60 | 2019-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Women'S Health, INC. | $77.61 | 2023 | Myrisk |
| Duchesnay USA Incorporated | $68.81 | 2019 | |
| Pfizer INC. | $66.01 | 2019-2023 | |
| Therapeuticsmd, INC. | $61.82 | 2019-2022 | |
| Scynexis, INC. | $58.84 | 2022 | |
| Hologic Sales and Service, LLC | $51.12 | 2024 | Aptima |
| Vertical Pharmaceuticals, LLC | $41.20 | 2019 | |
| Coopersurgical, INC. | $35.54 | 2019-2020 | |
| Medicem INC. | $32.76 | 2021 | |
| Evofem Biosciences, INC. | $31.89 | 2020-2021 | |
| Aspira Women'S Health INC | $24.81 | 2024 | Ova1 |
| Exact Sciences Corporation | $20.07 | 2023 | Cologuard Collection Kit |
| Gynesonics, INC. | $19.24 | 2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Davol INC. | $16.47 | 2022 | |
| Ascend Therapeutics US, LLC | $14.97 | 2023 | |
| Millicent US INC | $14.34 | 2025 | Femlyv, Intrarosa |
| Meditrina | $13.49 | 2025 | |
| Lupin INC. | $11.98 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilo Gonima listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.